In addition, pharmacodynamic changes might result in increased sensitivity to a given drug, including treatment resistance. "Another problem is polypharmacy, such as someone who takes bupropion with paroxetine or fluoxetine, Dr. Lenze said. "Those two drugs interact, sometimes pushing the levels of bupropion to toxic ranges. The other bad kind of polypharmacy is taking multiple anticholinergics or sedatives that provide cumulative risk."
Dr. Wetherell said she had no relevant financial conflicts to disclose.
Dr. Lenze disclosed that he has received grant support from Roche, Lundbeck, and Johnson & Johnson.